Sister Beth Davies—Purdue Pharma

Sister Beth Davies—Purdue Pharma is a relationship of resistance rather than formal partnership or legal confrontation: Purdue Pharma sought to promote OxyContin, while Sister Beth Davies refused to be swayed by the company’s marketing or its offers of money. The book sets this opposition against her decades of activism and the growing alarm over the drug in her community, showing how corporate influence met a local critic who would not yield.

Sister Beth Davies’s Prior Activism

Before her opposition to Purdue Pharma, Sister Beth Davies had spent decades standing up to coal-mining operators. That history matters to the relationship: she was not encountering corporate influence for the first time when Purdue’s sales efforts reached the region. The book describes her as a forceful activist whose independence was not easily softened by offers from powerful organizations.

Purdue Pharma’s Promotion and the Local Warning Signs

Purdue Pharma promoted OxyContin by emphasizing its safety and the low risk of addiction when it was taken as prescribed. The company’s message was part of a broader sales effort that presented opioid prescribing as responsible treatment for pain, including pain unrelated to cancer. In the late 1990s, however, warning signs were already visible in the communities where the drug was circulating: a pharmacist in Pennington Gap had experienced robbery attempts, including one involving the OxyContin-addicted son of a local hair-salon owner, and a confidential informant told a Big Stone Gap police lieutenant that OxyContin was already being sold on the street.

These reports provide the immediate community context for Sister Beth Davies’s resistance. The conflict was not only over a company’s public claims about a medicine; it was also over what residents and local professionals were seeing as the drug entered everyday life. The book does not describe Sister Beth as the source of these warnings, but places her opposition within the same accumulating local alarm.

Refusing the Company’s Influence

The clearest account of the relationship is that Sister Beth Davies refused to be swayed by Purdue Pharma’s marketing or its offers of money. The book characterizes those offers as an attempt to exert influence and describes her as someone who would not accept it. Its comparison is pointed: Purdue Pharma’s executives might have been able to intimidate people farther north, where the company’s philanthropy carried weight, but that approach did not work with Sister Beth.

Her refusal connects her earlier activism against coal operators with her response to Purdue Pharma. In both contexts, the narrative emphasizes her willingness to stand against powerful interests rather than treat their resources or status as reasons to defer. The evidence supports this as a moral and public opposition, not as a documented lawsuit or a formal campaign organized by Sister Beth against the company.

The Limits of Corporate Power

The relationship also exposes a contrast between Purdue Pharma’s broad promotional reach and the unevenness of its influence. The company could make safety claims through a large sales operation and cultivate authority through its public standing, but Sister Beth Davies’s prior experience as an activist made her resistant to that kind of persuasion. Her opposition gives the larger story a local counterweight: the company’s message did not go uncontested, even in communities where its drug was already appearing on the street.

The book’s account does not claim that Sister Beth alone could stop Purdue Pharma’s marketing or reverse OxyContin’s spread. Its significance is narrower and more personal: she declined the company’s overtures and retained her independence at a time when the harms emerging around the drug were becoming harder for local observers to ignore.